Beta Drugs Limited has informed about their 2024-25 investor presentation, highlighting strong growth in domestic brands and international business, surpassing 100 Cr in domestic oncology sales, with a robust EBITA margin of 22.4%. They emphasize R&D
AI Assistant
Beta Drugs Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.